CD38 and acute lymphoblastic leukemia: A preclinical study showed that isatuximab has significant in vitro and in vivo activity against ALL cells with a robust ADCC and ADCP effect that is clearly correlated with CD38 expression levels in both T‐ALL and B cell‐acute lymphoblastic leukemia (B‐ALL)14 The purpose of the study was to evaluate the efficacy and safety of isatuximab monotherapy in patients with relapsed or refractory T‐ALL or T‐LBL.